TWI222879B - Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder - Google Patents
Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder Download PDFInfo
- Publication number
- TWI222879B TWI222879B TW089102338A TW89102338A TWI222879B TW I222879 B TWI222879 B TW I222879B TW 089102338 A TW089102338 A TW 089102338A TW 89102338 A TW89102338 A TW 89102338A TW I222879 B TWI222879 B TW I222879B
- Authority
- TW
- Taiwan
- Prior art keywords
- todotin
- release
- composition according
- concentration
- controlled release
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000003932 urinary bladder Anatomy 0.000 title 1
- 238000013270 controlled release Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 229910052704 radon Inorganic materials 0.000 claims description 17
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 17
- 239000007937 lozenge Substances 0.000 claims description 13
- 230000002079 cooperative effect Effects 0.000 claims description 6
- 206010020853 Hypertonic bladder Diseases 0.000 abstract description 17
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 6
- 229960004045 tolterodine Drugs 0.000 abstract description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 238000011049 filling Methods 0.000 description 16
- 239000002207 metabolite Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 206010013781 dry mouth Diseases 0.000 description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 13
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960005434 oxybutynin Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 208000020629 overactive bladder Diseases 0.000 description 9
- 210000003296 saliva Anatomy 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 6
- 229940025084 amphetamine Drugs 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000002636 mycotoxin Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 2 — phenyl-5-tolyl Chemical group 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 231100000678 Mycotoxin Toxicity 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- UAGMSGKBTBVFJD-UHFFFAOYSA-L C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].[Na+].C(CO)(=O)[O-] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].[Na+].C(CO)(=O)[O-] UAGMSGKBTBVFJD-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DSJYSRTZHXBOCX-UHFFFAOYSA-N ac1l9i4c Chemical compound O.O.O.O DSJYSRTZHXBOCX-UHFFFAOYSA-N 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI222879B true TWI222879B (en) | 2004-11-01 |
Family
ID=20413266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089102332A TWI267385B (en) | 1998-11-11 | 2000-02-11 | Controlled release bead, pharmaceutical formulation comprising the same and production thereof |
| TW089102338A TWI222879B (en) | 1998-11-11 | 2000-02-11 | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089102332A TWI267385B (en) | 1998-11-11 | 2000-02-11 | Controlled release bead, pharmaceutical formulation comprising the same and production thereof |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6911217B1 (de) |
| EP (1) | EP1128819B1 (de) |
| JP (1) | JP3616011B2 (de) |
| KR (1) | KR100467384B1 (de) |
| CN (1) | CN1169522C (de) |
| AP (1) | AP1323A (de) |
| AR (1) | AR027815A1 (de) |
| AT (1) | ATE247458T1 (de) |
| AU (1) | AU762410B2 (de) |
| BG (1) | BG65149B1 (de) |
| BR (1) | BRPI9915142B8 (de) |
| CA (1) | CA2350061C (de) |
| CZ (1) | CZ299582B6 (de) |
| DE (1) | DE69910604T2 (de) |
| DK (1) | DK1128819T3 (de) |
| EA (1) | EA005074B1 (de) |
| EE (1) | EE05232B1 (de) |
| ES (1) | ES2204193T3 (de) |
| GE (1) | GEP20022833B (de) |
| HK (1) | HK1040917B (de) |
| HR (1) | HRP20010333B1 (de) |
| HU (1) | HU226582B1 (de) |
| ID (1) | ID30039A (de) |
| IL (1) | IL142809A0 (de) |
| IS (1) | IS2370B (de) |
| MA (1) | MA25325A1 (de) |
| MY (1) | MY122195A (de) |
| NO (1) | NO331399B1 (de) |
| NZ (1) | NZ511430A (de) |
| OA (1) | OA11673A (de) |
| PL (1) | PL195780B1 (de) |
| PT (1) | PT1128819E (de) |
| RS (1) | RS49891B (de) |
| SE (1) | SE9803871D0 (de) |
| SI (1) | SI1128819T1 (de) |
| SK (1) | SK284758B6 (de) |
| TW (2) | TWI267385B (de) |
| UA (1) | UA57165C2 (de) |
| WO (1) | WO2000027364A1 (de) |
| ZA (1) | ZA200103575B (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000515525A (ja) * | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| EP0957073A1 (de) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | 3,3-Diphenylpropylaminderivate |
| NZ518309A (en) | 1999-11-11 | 2003-05-30 | Pharmacia Ab | Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours |
| JP2006500381A (ja) * | 2002-08-28 | 2006-01-05 | ファルマシア・コーポレーション | 経口投与用液体トルテロジン組成物 |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| MXPA05007767A (es) * | 2003-01-22 | 2006-01-31 | Pfizer Health Ab | Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios. |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| WO2004112756A1 (en) | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DK2210605T3 (en) | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
| US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| EP1629834A1 (de) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung |
| EP1836156A1 (de) * | 2005-01-10 | 2007-09-26 | Teva Gyogyszergyar Reszvenytarsasag | Im wesentlichen reines tolterodintartrat und verfahren zu dessen herstellung |
| ATE512211T1 (de) | 2005-05-31 | 2011-06-15 | Iams Company | Feline probiotische lactobacilli |
| AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| HUE043365T2 (hu) | 2006-01-18 | 2019-08-28 | Intec Pharma Ltd | Kiadóberendezés szer orális bevételéhez |
| SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
| KR100714058B1 (ko) * | 2006-02-06 | 2007-05-02 | 한국유나이티드제약 주식회사 | 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법 |
| CA2642340A1 (en) * | 2006-02-24 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Metoprolol succinate e.r. tablets and methods for their preparation |
| EP1996169A2 (de) * | 2006-03-21 | 2008-12-03 | Teva Pharmaceutical Industries Ltd | Kontrollierte abgabe von tolterodinformulierungen |
| EP1839649A1 (de) * | 2006-03-31 | 2007-10-03 | LEK Pharmaceuticals D.D. | Beschichtete Formulierung von Tolterodine |
| CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| EP2015735A1 (de) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodin-perlen |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2007131804A1 (en) | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
| HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
| JP2008007458A (ja) * | 2006-06-29 | 2008-01-17 | Freunt Ind Co Ltd | レイヤリング用核粒子とその製造方法 |
| EA201300152A1 (ru) | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
| EP2124966B1 (de) | 2007-02-01 | 2015-09-09 | IAMS Europe B.V. | Verfahren zur verringerung von entzündung und oxidativem stress bei einem säugetier mit glucose-antimetaboliten, avocado oder avocado-extrakten |
| DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
| PL2148661T3 (pl) | 2007-04-25 | 2013-07-31 | Cytochroma Inc | Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik |
| PT3335712T (pt) | 2007-04-25 | 2025-10-23 | Opko Renal Llc | Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica |
| EP2173329A1 (de) * | 2007-07-03 | 2010-04-14 | Synthon B.V. | Tolterodinkügelchen |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| US8486452B2 (en) | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| WO2009019599A2 (en) * | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| CA2629099A1 (en) * | 2008-04-01 | 2009-10-01 | Pharmascience Inc. | Novel oral controlled release pharmaceutical formulations |
| CN102046812A (zh) | 2008-04-02 | 2011-05-04 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| US20090311317A1 (en) * | 2008-05-14 | 2009-12-17 | Capricorn Pharma Inc. | Modified release tolterodine formulations |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US8465770B2 (en) | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| WO2011013082A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| WO2011061616A2 (en) | 2009-11-23 | 2011-05-26 | Micro Labs Limited | Extended release compositions containing tolterodine and process for preparing the same |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
| RU2566269C2 (ru) | 2010-03-29 | 2015-10-20 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
| JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| JP5812500B2 (ja) | 2010-04-30 | 2015-11-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規なβ３アドレナリン作動性受容体アゴニスト |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120289560A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| GR1007628B (el) | 2011-07-27 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| CN103781467B (zh) | 2011-09-16 | 2016-08-31 | 辉凌公司 | 一种快速溶解药物组合物 |
| JP5553132B2 (ja) * | 2011-09-30 | 2014-07-16 | アステラス製薬株式会社 | 粒子状医薬組成物 |
| CN104428003B (zh) | 2012-07-12 | 2020-03-10 | 辉凌公司 | 双氯芬酸制剂 |
| AU2013317842A1 (en) * | 2012-09-20 | 2015-04-30 | Ohr Pharma, Llc | Multilayer biodegradable microparticles for sustained release of therapeutic agents |
| US20150306170A1 (en) * | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| ES2796835T3 (es) * | 2013-03-13 | 2020-11-30 | Intervet Int Bv | Sustancias bioactivas estables y métodos de fabricación |
| WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| AU2014246617A1 (en) | 2013-12-23 | 2015-07-09 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CA2902911C (en) * | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2017146053A1 (ja) * | 2016-02-23 | 2017-08-31 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤 |
| MY198547A (en) | 2016-03-28 | 2023-09-04 | Opko Ireland Global Holdings Ltd | Methods of vitamin d treatment |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1144911B (it) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
| JPH07107450A (ja) | 1993-10-08 | 1995-04-21 | Hitachi Ltd | 情報通信装置 |
| JP3453186B2 (ja) | 1994-04-14 | 2003-10-06 | 共和薬品工業株式会社 | 徐放性マイクロカプセルおよびその製造方法 |
| SE9402422D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| US5645858A (en) * | 1994-10-06 | 1997-07-08 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| US6312728B1 (en) * | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
-
1998
- 1998-11-11 SE SE9803871A patent/SE9803871D0/xx unknown
-
1999
- 1999-11-11 ID IDW00200101038A patent/ID30039A/id unknown
- 1999-11-11 OA OA1200100112A patent/OA11673A/en unknown
- 1999-11-11 NZ NZ511430A patent/NZ511430A/en not_active IP Right Cessation
- 1999-11-11 WO PCT/SE1999/002052 patent/WO2000027364A1/en not_active Ceased
- 1999-11-11 EP EP99971702A patent/EP1128819B1/de not_active Expired - Lifetime
- 1999-11-11 HU HU0105038A patent/HU226582B1/hu unknown
- 1999-11-11 IL IL14280999A patent/IL142809A0/xx unknown
- 1999-11-11 EE EEP200100254A patent/EE05232B1/xx unknown
- 1999-11-11 GE GEAP19995939A patent/GEP20022833B/en unknown
- 1999-11-11 HK HK02102521.2A patent/HK1040917B/zh not_active IP Right Cessation
- 1999-11-11 CZ CZ20011627A patent/CZ299582B6/cs not_active IP Right Cessation
- 1999-11-11 BR BRPI9915142A patent/BRPI9915142B8/pt not_active IP Right Cessation
- 1999-11-11 JP JP2000580595A patent/JP3616011B2/ja not_active Expired - Lifetime
- 1999-11-11 DE DE69910604T patent/DE69910604T2/de not_active Expired - Lifetime
- 1999-11-11 MY MYPI99004911A patent/MY122195A/en unknown
- 1999-11-11 ES ES99971702T patent/ES2204193T3/es not_active Expired - Lifetime
- 1999-11-11 PT PT99971702T patent/PT1128819E/pt unknown
- 1999-11-11 AU AU14366/00A patent/AU762410B2/en not_active Expired
- 1999-11-11 RS YUP-331/01A patent/RS49891B/sr unknown
- 1999-11-11 AP APAP/P/2001/002166A patent/AP1323A/en active
- 1999-11-11 EA EA200100538A patent/EA005074B1/ru not_active IP Right Cessation
- 1999-11-11 PL PL99348612A patent/PL195780B1/pl unknown
- 1999-11-11 AR ARP990105734A patent/AR027815A1/es active IP Right Grant
- 1999-11-11 AT AT99971702T patent/ATE247458T1/de active
- 1999-11-11 HR HR20010333A patent/HRP20010333B1/xx not_active IP Right Cessation
- 1999-11-11 UA UA2001042824A patent/UA57165C2/uk unknown
- 1999-11-11 CA CA002350061A patent/CA2350061C/en not_active Expired - Lifetime
- 1999-11-11 SK SK625-2001A patent/SK284758B6/sk not_active IP Right Cessation
- 1999-11-11 US US09/763,281 patent/US6911217B1/en not_active Expired - Lifetime
- 1999-11-11 CN CNB998132160A patent/CN1169522C/zh not_active Expired - Lifetime
- 1999-11-11 KR KR10-2001-7005879A patent/KR100467384B1/ko not_active Expired - Lifetime
- 1999-11-11 SI SI9930411T patent/SI1128819T1/xx unknown
- 1999-11-11 DK DK99971702T patent/DK1128819T3/da active
-
2000
- 2000-02-11 TW TW089102332A patent/TWI267385B/zh not_active IP Right Cessation
- 2000-02-11 TW TW089102338A patent/TWI222879B/zh not_active IP Right Cessation
-
2001
- 2001-05-03 ZA ZA200103575A patent/ZA200103575B/en unknown
- 2001-05-09 IS IS5936A patent/IS2370B/is unknown
- 2001-05-10 NO NO20012314A patent/NO331399B1/no not_active IP Right Cessation
- 2001-06-08 MA MA26228A patent/MA25325A1/fr unknown
- 2001-06-08 BG BG105582A patent/BG65149B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI222879B (en) | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder | |
| ES2353765T3 (es) | Formulación terapeútica para administrar tolterodina con liberación controlada. | |
| EP1039882B1 (de) | Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung | |
| KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| KR100838930B1 (ko) | 톨테로딘을 포함하는 약학 제제 및 이의 용도 | |
| JP3580815B2 (ja) | 安定な徐放性経口投与組成物 | |
| JP5158919B2 (ja) | 延長放出経口用量組成物 | |
| JP5561885B2 (ja) | ミルタザピンの新しい配合物 | |
| US20030228359A1 (en) | Pharmaceutical formulations containing epinastine, belladonna, and pseudoephedrine | |
| US20050084527A1 (en) | Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine | |
| CN101756981A (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
| JP2003523981A (ja) | モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤 | |
| WO2025054280A1 (en) | Formulations of stat3 inhibitors and methods of use thereof | |
| JP2002523358A (ja) | ナプロキセンおよびプソイドエフェドリンを含む徐法性錠剤 | |
| TW202513044A (zh) | 丙磺舒調配物 | |
| KR101199654B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| MXPA00005215A (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| HK1034664B (en) | Therapeutic formulation for administering tolterodine with controlled release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |